Progression of glucose-lowering diabetes therapy in TECOS-Reference-Cited by-同舟云学术

Progression of glucose-lowering diabetes therapy in TECOS

Published:2018-12-22 Issue:1 Volume:2 Page:e00053
ISSN:2398-9238
Container-title:Endocrinology, Diabetes & Metabolism
language:en
Short-container-title:Endocrinol Diab Metab

Author:

Bethel M. Angelyn¹,Engel Samuel S.²^ORCID,Stevens Susanna R.³,Lokhnygina Yuliya³,Ding Jie⁴,Josse Robert G.⁵,Alvarsson Michael⁶,Hramiak Irene⁷,Green Jennifer B.³,Peterson Eric D.³,Holman Rury R.¹^ORCID,

Affiliation:

1. Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism; University of Oxford; Oxford UK

2. Merck & Co., Inc; Kenilworth New Jersey

3. Duke Clinical Research Institute; Duke University School of Medicine; Durham North Carolina

4. Merck Sharp & Dohme (China); Beijing China

5. St. Michael's Hospital; University of Toronto; Toronto Ontario Canada

6. Department of Endocrinology; Karolinska University Hospital; Stockholm Sweden

7. University of Western Ontario; London Ontario Canada

Funder

Merck Sharp and Dohme

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/edm2.53/fullpdf

Reference21 articles.

1. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57);Wright;Diabetes Care,2002

2. Swedish National Diabetes Register https://www.ndr.nu/#/knappen

3. Centers for Disease Control and Prevention Age-adjusted percentage of adults with diabetes using diabetes medication, by type of medication, United States, 1997-2011 https://www.cdc.gov/diabetes/statistics/meduse/fig2.htm

4. Barriers and facilitators to starting insulin in patients with type 2 diabetes: a systematic review;Ng;Int J Clin Pract,2015

5. Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration;Abu Hassan;BMC Fam Pract,2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis;Cochrane Database of Systematic Reviews;2021-10-25

2. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Italian cohorts;Diabetes, Obesity and Metabolism;2021-03-15

3. Ethyl Acetate Fraction of Helianthus tuberosus L. Induces Anti-Diabetic, and Wound-Healing Activities in Insulin-Resistant Human Liver Cancer and Mouse Fibroblast Cells;Antioxidants;2021-01-12

4. The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes;Metabolism;2020-08

5. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial;European Journal of Heart Failure;2020-07-28